RNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes.

ABSTRACT:

Background

The translocation t(9;11)(p22;q23) leading to the leukemogenic fusion gene MLL-AF9 is a frequent translocation in infant acute myeloid leukemia (AML). This study aimed to identify genes and molecular processes downstream of MLL-AF9 (alias MLL-MLLT3) which could assist to develop new targeted therapies for such leukemia with unfavorable prognosis.

Methods

In the AML cell line THP1 which harbors this t(9;11) translocation, endogenous MLL-AF9 was silenced via siRNA while ensuring specificity of the knockdown and its efficiency on functional protein level.

Results

The differential gene expression profile was validated for leukemia-association by gene set enrichment analysis of published gene sets from patient studies and MLL-AF9 overexpression studies and revea

SUBMITTER: Fleischmann KK 

PROVIDER: S-EPMC3924703 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature